Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market
2 posters
Page 1 of 1
Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market
After decades without effective medications to prevent migraines, sufferers may have new options coming to the market soon. Two new drugs targeting the same pathway in the brain may cut down on the number and the length of migraines people suffer, separate studies published Wednesday in the New England Journal of Medicine have shown.
Migraines are not just headaches. There is a headache involved, certainly, but migraine pain is far more severe. People may also be extremely sensitive to light and sound while a migraine is happening and even vomit. Some people can predict when a migraine will next strike because of warning signs they feel, called auras. According to MedlinePlus, up to 12 percent of Americans have migraines.
Currently, the most effective drugs used to treat migraines are primarily designed to be used once a migraine starts. People may also adjust their lives to avoid things that trigger the migraines or use drugs not intended to specifically treat migraines.
People with migraines are thought to have too much of a protein called calcitonin gene-related peptide (CGRP) in their brains; both drugs work to try and reduce the effect of CGRP on neurons in different ways. One,fremanezumab, binds to CGRP directly so it can’t bind to brain cells and have an effect. The other, erenumab, blocks the receptor on brain cells to which CGRP binds.
“These drugs may find a specific role in the treatment of patients who have migraines that are refractory to treatment or who are severely disabled by headaches,” wrote from the Cincinnati Children’s Hospital Medical Center in an editorial that accompanied the studies.
One of the authors of the erenumab study was more direct about the drug’s potential impact in an interview with the BBC. "It's a huge deal because it offers an advance in understanding the disorder and a designer migraine treatment,” Dr. Peter Goadsby at King’s College Hospital said. "These patients will have parts of their life back and society will have these people back functioning."
In addition to acting differently, the two drugs were also tested for different types of migraines: episodic vs. chronic. People with chronic migraines have more episodes over a longer period of time than those with episodic migraines. One drug, erenumab, was used specifically to prevent episodic migraines.
The study followed nearly 1,000 people over six months and tested two different dosages of the drug. When patients began the trial, most were suffering from migraines at least eight days each month. About half of the patients taking the drug had at least three to four fewer migraine days per month than they were having before, regardless of the dose.
Similar results were seen for fremanezumab, which was tested for chronic migraine patients. On average, patients who took the drug—regardless of the dosing schedule, which was either once every three months or once every month—had about four fewer days with headaches than those who were on a placebo drug. About 40 percent of the patients on the drug had half as many headache days on the drug. At the beginning of the trial, the average person was affected for nearly half of the month.
Each of the studies were funded by the companies developing the drugs; Amgen and Novartis are responsible for erenumab, while Teva is working on fremanezumab.
According to Amgen’s pipeline, which lists all the drugs the company is currently developing, erenumab will be called Aimovig when and if it reaches the U.S. market. (Amgen is developing the drug with Novartis.) The FDA may approve the drug for one group of migraine patients—those who have at least four migraine days per month—in May.
Teva is the pharmaceutical company behind second drug, fremanezuma, intended to treat chronic migraines. The company just submitted an application to the FDA for the drug’s approval in October.
https://www.goodnewsnetwork.org/two-breakthrough-drugs-treat-migraines-may-soon-hit-market/
Migraines are not just headaches. There is a headache involved, certainly, but migraine pain is far more severe. People may also be extremely sensitive to light and sound while a migraine is happening and even vomit. Some people can predict when a migraine will next strike because of warning signs they feel, called auras. According to MedlinePlus, up to 12 percent of Americans have migraines.
Currently, the most effective drugs used to treat migraines are primarily designed to be used once a migraine starts. People may also adjust their lives to avoid things that trigger the migraines or use drugs not intended to specifically treat migraines.
People with migraines are thought to have too much of a protein called calcitonin gene-related peptide (CGRP) in their brains; both drugs work to try and reduce the effect of CGRP on neurons in different ways. One,fremanezumab, binds to CGRP directly so it can’t bind to brain cells and have an effect. The other, erenumab, blocks the receptor on brain cells to which CGRP binds.
“These drugs may find a specific role in the treatment of patients who have migraines that are refractory to treatment or who are severely disabled by headaches,” wrote from the Cincinnati Children’s Hospital Medical Center in an editorial that accompanied the studies.
One of the authors of the erenumab study was more direct about the drug’s potential impact in an interview with the BBC. "It's a huge deal because it offers an advance in understanding the disorder and a designer migraine treatment,” Dr. Peter Goadsby at King’s College Hospital said. "These patients will have parts of their life back and society will have these people back functioning."
In addition to acting differently, the two drugs were also tested for different types of migraines: episodic vs. chronic. People with chronic migraines have more episodes over a longer period of time than those with episodic migraines. One drug, erenumab, was used specifically to prevent episodic migraines.
The study followed nearly 1,000 people over six months and tested two different dosages of the drug. When patients began the trial, most were suffering from migraines at least eight days each month. About half of the patients taking the drug had at least three to four fewer migraine days per month than they were having before, regardless of the dose.
Similar results were seen for fremanezumab, which was tested for chronic migraine patients. On average, patients who took the drug—regardless of the dosing schedule, which was either once every three months or once every month—had about four fewer days with headaches than those who were on a placebo drug. About 40 percent of the patients on the drug had half as many headache days on the drug. At the beginning of the trial, the average person was affected for nearly half of the month.
Each of the studies were funded by the companies developing the drugs; Amgen and Novartis are responsible for erenumab, while Teva is working on fremanezumab.
According to Amgen’s pipeline, which lists all the drugs the company is currently developing, erenumab will be called Aimovig when and if it reaches the U.S. market. (Amgen is developing the drug with Novartis.) The FDA may approve the drug for one group of migraine patients—those who have at least four migraine days per month—in May.
Teva is the pharmaceutical company behind second drug, fremanezuma, intended to treat chronic migraines. The company just submitted an application to the FDA for the drug’s approval in October.
https://www.goodnewsnetwork.org/two-breakthrough-drugs-treat-migraines-may-soon-hit-market/
Guest- Guest
Re: Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market
You can also have the aura without a headache. I know a few people who do, including myself. I wouldn't bother with a drug for it though - it passes on its own. For those who get headache and feel awful, I hope something works for them.
Raggamuffin- Forum Detective ????♀️
- Posts : 33746
Join date : 2014-02-10
Re: Two Breakthrough Drugs to Treat Migraines May Soon Hit the Market
Raggamuffin wrote:You can also have the aura without a headache. I know a few people who do, including myself. I wouldn't bother with a drug for it though - it passes on its own. For those who get headache and feel awful, I hope something works for them.
My eyesight gets fuzzy, I get a bad taste in my mouth and then I throw up. Some can last 1-2 hours, others for days. There is no reason (wine, chocolate, food additives etc...) and they are random. If it goes beyond 4 hours of lying in the dark I take the big pills and try and sleep through it, but as you know, it hurts to breath.
I hope this breakthrough works. I know people who are much worse than I am.
Cass- the Nerd Queen of Nerds, the Lover of Books who Cooks
- Posts : 6617
Join date : 2014-01-19
Age : 56
Similar topics
» How sugar feeds cancer and makes it harder to treat, according to 'breakthrough' study
» FDA Approves First Ever Drug Designed Exclusively to Prevent Migraines
» Migraines could be an immune system disease, opening up new treatment paths
» Migraines Could Be Caused By Bacteria Found In Your Mouth, Study Finds
» ‘Remarkable’ Blood Flow Discovery Could Pave the Way to New Treatments for Dementia and Migraines
» FDA Approves First Ever Drug Designed Exclusively to Prevent Migraines
» Migraines could be an immune system disease, opening up new treatment paths
» Migraines Could Be Caused By Bacteria Found In Your Mouth, Study Finds
» ‘Remarkable’ Blood Flow Discovery Could Pave the Way to New Treatments for Dementia and Migraines
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Mar 18, 2023 12:28 pm by Ben Reilly
» TOTAL MADNESS Great British Railway Journeys among shows flagged by counter terror scheme ‘for encouraging far-right sympathies
Wed Feb 22, 2023 5:14 pm by Tommy Monk
» Interesting COVID figures
Tue Feb 21, 2023 5:00 am by Tommy Monk
» HAPPY CHRISTMAS.
Sun Jan 01, 2023 7:33 pm by Tommy Monk
» The Fight Over Climate Change is Over (The Greenies Won!)
Thu Dec 15, 2022 3:59 pm by Tommy Monk
» Trump supporter murders wife, kills family dog, shoots daughter
Mon Dec 12, 2022 1:21 am by 'Wolfie
» Quill
Thu Oct 20, 2022 10:28 pm by Tommy Monk
» Algerian Woman under investigation for torture and murder of French girl, 12, whose body was found in plastic case in Paris
Thu Oct 20, 2022 10:04 pm by Tommy Monk
» Wind turbines cool down the Earth (edited with better video link)
Sun Oct 16, 2022 9:19 am by Ben Reilly
» Saying goodbye to our Queen.
Sun Sep 25, 2022 9:02 pm by Maddog
» PHEW.
Sat Sep 17, 2022 6:33 pm by Syl
» And here's some more enrichment...
Thu Sep 15, 2022 3:46 pm by Ben Reilly
» John F Kennedy Assassination
Thu Sep 15, 2022 3:40 pm by Ben Reilly
» Where is everyone lately...?
Thu Sep 15, 2022 3:33 pm by Ben Reilly
» London violence over the weekend...
Mon Sep 05, 2022 2:19 pm by Tommy Monk
» Why should anyone believe anything that Mo Farah says...!?
Wed Jul 13, 2022 1:44 am by Tommy Monk
» Liverpool Labour defends mayor role poll after turnout was only 3% and they say they will push ahead with the option that was least preferred!!!
Mon Jul 11, 2022 1:11 pm by Tommy Monk
» Labour leader Keir Stammer can't answer the simple question of whether a woman has a penis or not...
Mon Jul 11, 2022 3:58 am by Tommy Monk
» More evidence of remoaners still trying to overturn Brexit... and this is a conservative MP who should be drummed out of the party and out of parliament!
Sun Jul 10, 2022 10:50 pm by Tommy Monk
» R Kelly 30 years, Ghislaine Maxwell 20 years... but here in UK...
Fri Jul 08, 2022 5:31 pm by Original Quill